Monday, 12 August 2013

Researchers use iPSCs technology to mass produce reprogrammed T cells that target cancer cells

In a new study, researchers at the Memorial Sloan-Kettering Cancer Centre have shown how stem cell technology can be used to mass-produce cancer-killing immune cells designed to target different kinds of cancers and tumours, with their research opening up the prospect of immunotherapy treatments that may one day help a lot of patients.

In theory cancer can be tackled by elements of the body's own immune defences, especially white blood cells called T-cells.


But in practice, T-cells that target and kill cancer cells while ignoring healthy cells are very rare, and progress towards immune-based cancer treatments has been limited.

The new approach provides a way to reprogramme T-cells and develop large amounts of them "off the shelf" primed to attack specific cancers.

A small number of healthy human T-cells were first reprogrammed into malleable stem cells with embryonic properties, US scientists reported in the journal Nature Biotechnology.

These induced pluripotent stem cells (iPScs) were then manipulated to produce a tumour-specific receptor molecule on their surfaces.

Finally, the stem cells were coaxed to re-acquire their original T-cell properties while expanding to large numbers.

Each of the T-cells now had the all-important receptor that allowed it to target a particular cancer "antigen" or protein, in this case lymphoma.

Injected into mice with a human form of lymphoma, the lab-grown T-cells significantly suppressed tumour growth and increased survival.

The researchers, led by Dr Michel Sadelain from Memorial Sloan-Kettering Cancer Centre in New York City, wrote:

"This approach of generating therapeutic human T cells 'in the dish' may be useful for cancer immunotherapy and other medical applications."
Reference
Maria Themeli, Christopher C Kloss, Giovanni Ciriello, Victor D Fedorov, Fabiana Perna, Mithat Gonen & Michel Sadelain (2013). Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy Nature Biotechnology DOI: 10.1038/nbt.2678

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !